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Abstract. 
 
Although the interaction of matrix proteins 
with integrins is known to initiate signaling pathways 
that are essential for cell survival, a role for tumor sup-
pressors in the regulation of these pathways has not 
been established. We demonstrate here that p53 can in-
hibit the survival function of integrins by inducing the 
caspase-dependent cleavage and inactivation of the 
serine/threonine kinase AKT/PKB. Speciﬁcally, we 
show that the 
 
a
 
6
 
b
 
4 integrin promotes the survival of 
p53-deﬁcient carcinoma cells by activating AKT/PKB. 
In contrast, this integrin does not activate AKT/PKB in 
carcinoma cells that express wild-type p53 and it actu-
ally stimulates their apoptosis, in agreement with our 
previous ﬁndings (Bachelder, R.E., A. Marchetti, R. 
Falcioni, S. Soddu, and A.M. Mercurio. 1999. 
 
J. Biol. 
Chem.
 
 274:20733–20737). Interestingly, we observed re-
duced levels of AKT/PKB protein after antibody clus-
tering of 
 
a
 
6
 
b
 
4 in carcinoma cells that express wild-type 
p53. In contrast, 
 
a
 
6
 
b
 
4 clustering did not reduce the 
level of AKT/PKB in carcinoma cells that lack func-
tional p53. The involvement of caspase 3 in AKT/PKB 
 
regulation was indicated by the ability of Z-DEVD-FMK, 
a caspase 3 inhibitor, to block the 
 
a
 
6
 
b
 
4-associated re-
duction in AKT/PKB levels in vivo, and by the ability of 
recombinant caspase 3 to promote the cleavage of 
AKT/PKB in vitro. In addition, the ability of 
 
a
 
6
 
b
 
4 to 
activate AKT/PKB could be restored in p53 wild-type 
carcinoma cells by inhibiting caspase 3 activity. These 
studies demonstrate that the p53 tumor suppressor can 
inhibit integrin-associated survival signaling pathways.
Key words: p53 • integrin • AKT/PKB • survival • 
caspase
 
P
 
RIMARY
 
 epithelial (Frisch and Francis, 1994) and en-
dothelial (Meredith et al., 1993) cells are prone to
anoikis, a form of programmed cell death, when
grown in the absence of growth factors and extracellular
matrix proteins. This default apoptotic pathway is thought
to be important in preventing cell growth at inappropriate
anatomical sites. Survival signaling pathways associated
with both growth factor receptors and cell adhesion mole-
cules are important in protecting cells from anoikis. For
example, growth factors such as EGF, PDGF, and insulin
can promote the survival of serum-starved epithelial cells
(Merlo et al., 1995; Rampalli and Zelenka, 1995; Rodeck
et al., 1997). Similarly, the binding of integrins such as
 
a
 
v
 
b
 
3 (Stromblad et al., 1996), 
 
a
 
5
 
b
 
1 (Zhang et al., 1995),
and 
 
a
 
6
 
b
 
1 (Howlett et al., 1995; Wewer et al., 1997; Far-
relly et al., 1999) to the appropriate extracellular matrix
protein can inhibit anoikis. These survival signals have
been attributed to the ability of integrins to activate nu-
merous molecules including focal adhesion kinase (Frisch
et al., 1996), integrin-linked kinase (Radeva et al., 1997),
AKT/PKB (Khwaja et al., 1997), and bcl-2 (Zhang et al.,
1995; Stromblad et al., 1996). In addition, integrin survival
functions have been associated with their ability to inhibit
the activity of p53 (Stromblad et al., 1996; Ilic et al., 1998)
and Rb (Day et al., 1997) tumor suppressors. Tumor cells
acquire a partial resistance to anoikis as a result of their
transformation, which is thought to activate select survival
signaling pathways in these cells constitutively (Frisch and
Francis, 1994). For this reason, the identification of mole-
cules that can inhibit survival signaling is crucial for devel-
oping strategies aimed at blocking tumor cell growth.
The 
 
a
 
6
 
b
 
4 integrin, a receptor for the laminin family of
extracellular matrix proteins, plays an important role in di-
verse cellular activities. In addition to serving an impor-
tant structural role in the assembly of hemidesmosomes in
epithelial cells (Borradori and Sonnenberg, 1996; Green
and Jones, 1996), 
 
a
 
6
 
b
 
4 promotes carcinoma cell migration
and invasion (Tozeren et al., 1994; Chao et al., 1996; Shaw
et al., 1997; O’Connor et al., 1998) in a phosphoinositide
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3-OH kinase–dependent manner (Shaw et al., 1997). The 
 
b
 
4
subunit of this integrin, which contains a cytoplasmic tail of
 
z
 
1,000 amino acids (Hemler et al., 1989; Kajiji et al., 1989;
Kennel et al., 1989), has been shown to be crucial in the
ability of this integrin to activate numerous signaling mole-
cules, including phosphoinositide 3-OH kinase (Shaw et al.,
1997), Shc (Mainiero et al., 1997), Ras (Mainiero et al.,
1997), Jnk (Mainiero et al., 1997), p21WAF1/CIP1 (Clarke
et al., 1995), and p53 (Bachelder et al., 1999). The diverse
activities of this integrin are exemplified by its ability to
promote both the survival of keratinocytes (Dowling et al.,
1996) as well as the apoptosis of a number of carcinoma cell
lines (Clarke et al., 1995; Kim et al., 1997; Sun et al., 1998;
Bachelder et al., 1999). These apparently contradictory
functions likely reflect the activation of distinct signaling
pathways by this integrin in different cell types as well as
the influence of other signaling pathways on 
 
a
 
6
 
b
 
4 function.
In the present study, we define opposing signaling path-
ways that are activated by the 
 
a
 
6
 
b
 
4 integrin that promote
either carcinoma cell survival or apoptosis, depending on
whether these cells express wild-type or functionally inac-
tive mutants of p53. Specifically, we show that 
 
a
 
6
 
b
 
4 can
promote the AKT/PKB–dependent survival of p53-defi-
cient carcinoma cells. However, this activity contrasts with
the ability of 
 
a
 
6
 
b
 
4 to stimulate the caspase-dependent
cleavage and inactivation of AKT/PKB in p53 wild-type
carcinoma cells. The ability of wild-type p53 to inhibit
 
a
 
6
 
b
 
4-associated survival signals suggests that the p53 sta-
tus of an 
 
a
 
6
 
b
 
4-expressing carcinoma cell influences its
growth potential.
 
Materials and Methods
 
Cells
 
The RKO colon carcinoma cell line was obtained from M. Brattain
(University of Texas, San Antonio, TX), and MDA-MB-435 breast carci-
noma cells were obtained from the Lombardi Breast Cancer Depository
(Georgetown University).
The cloning of the human 
 
b
 
4 cDNA, the construction of the 
 
b
 
4 cyto-
plasmic domain deletion mutant (
 
b
 
4-
 
D
 
cyt), and their insertions into the
pRc/CMV (
 
b
 
4) and pcDNA3 (
 
b
 
4-
 
D
 
cyt) eukaryotic expression vectors, re-
spectively, have been described (Clarke et al., 1995). RKO/
 
b
 
4
 
D
 
cyt clone
3E1, RKO/
 
b
 
4 clone D4 (RKO/
 
b
 
4 clone 1), RKO/
 
b
 
4 clone A7 (RKO/
 
b
 
4
clone 2), MDA-MB-435/
 
b
 
4-
 
D
 
cyt clone 3C12, MDA-MB-435/
 
b
 
4 clone 5B3
(MDA-MB-435/
 
b
 
4 clone 1), and MDA-MB-435/
 
b
 
4 clone 3A7 (MDA/
 
b
 
4
clone 2) were selected for analysis based on their expression of similar sur-
face levels of 
 
a
 
6
 
b
 
4 and 
 
a
 
6
 
b
 
4-
 
D
 
cyt, as we have previously demonstrated
(Clarke et al., 1995; Shaw et al., 1997; Bachelder et al., 1999).
Dominant negative p53-expressing RKO/
 
b
 
4-
 
D
 
cyt and RKO/
 
b
 
4 sub-
clones were obtained by cotransfecting RKO/
 
b
 
4-
 
D
 
cyt clone 3E1 and
RKO/
 
b
 
4 clone D4 with plasmids expressing the puromycin resistance
gene (Morgenstern and Land, 1990) and a dominant negative p53
(dnp53)
 
1
 
 construct (provided by M. Oren, Weizmann Institute for Science,
Israel) that encodes for a carboxy-terminal domain of p53 that can het-
erodimerize with endogenous p53 and inhibit its transcriptional activity.
Dnp53-expressing subclones were obtained and those subclones express-
ing high levels of dnp53 were selected by FACS using the Pab122 mAb
(Boehringer Mannhein), which recognizes a conserved, denaturation sta-
ble epitope in dnp53. In addition, RKO/
 
b
 
4 and RKO/
 
b
 
4-
 
D
 
cyt cells were
transfected with the puromycin resistance gene plasmid alone to obtain
puromycin-resistant mock transfectants. All assays were performed using
cell maintained below passage 10.
Stable transfectants of MDA/
 
b
 
4 clone 3A7 that expressed tempera-
ture-sensitive p53 were obtained by cotransfecting this cell line with plas-
mids expressing the puromycin resistance gene (1 mg) (Morgenstern and
Land, 1990) and a plasmid expressing a temperature-sensitive mutant of
human p53 (tsp53; 4 
 
m
 
g) that assumes a functional conformation at 32
 
8
 
C,
but not at 37
 
8
 
C (Zhang et al., 1994) using the Lipofectamine reagent
(GIBCO BRL). After growing these transfectants in complete medium
for 2 d, stable transfectants were selected by culturing these cells in puro-
mycin-containing medium (2 
 
m
 
g/ml) for an additional 18 d. These bulk
transfectants were expanded and tsp53 expression was confirmed by
showing increased p53 levels in tsp53 transfectants relative to mock trans-
fectants by immunoblotting with a goat anti-human p53, followed by
HRP-conjugated donkey anti–goat IgG. All assays were performed on
cells maintained below passage 5.
Dominant negative AKT (dnAKT)/PKB–expressing MDA-MB-435/
mock and MDA-MB-435/
 
b
 
4 transient transfectants were generated by
cotransfecting these cell lines using the Lipofectamine reagent (GIBCO
BRL) with a plasmid encoding for green fluorescent protein (pEGFP-1;
CLONTECH Laboratories; 1 
 
m
 
g) and a dnAKT/PKB construct that con-
tains inactivating mutations in the catalytic domain of AKT/PKB (4 
 
m
 
g)
(Dudek et al., 1997; Skorski et al., 1997; Eves et al., 1998).
 
Antibodies
 
The following antibodies were used: 439-9B, a rat mAb specific for the 
 
b
 
4
integrin subunit (Falcioni et al., 1998), control rat IgG (Sigma Chemical
Co.); Pab122, a polyclonal rabbit serum specific for p53 (Boehringer Mann-
heim); goat anti-human p53; rabbit polyclonal anti-AKT/PKB raised
against a peptide corresponding to mouse AKT/PKB residues 466–479
(New England Biolabs); rabbit polyclonal anti-AKT/PKB phosphoserine
473 (New England Biolabs); rabbit anti-actin (Sigma Chemical Co.); and
mouse anti-hemagglutinin (Boehringer Mannheim). Goat anti–mouse
IgG and goat anti–rat IgG secondary antibodies, as well as HRP conju-
gates of these antibodies, were obtained from Jackson ImmunoResearch
Laboratories, Inc. HRP-conjugated donkey anti–goat IgG was obtained
from BioSource International.
 
Apoptosis Assays
 
To induce apoptosis in the RKO and MDA-MB-435 transfectants, the
cells were plated in complete medium for 8 h in tissue culture wells (12-
well plate; 2.5 
 
3
 
 10
 
5
 
 cells/well) that had been coated overnight at 4
 
8
 
C with
poly-
 
L
 
-lysine (Sigma Chemical Co.; 2 ml of 25 
 
m
 
g/ml stock) and blocked
with 1% BSA. After 8 h, this medium was replaced with serum-free cul-
ture medium containing 1% BSA. After 15 h at 37
 
8
 
C, adherent and sus-
pension cells were harvested, combined, and the level of apoptosis in
these cells was assessed as described below.
For annexin V stains, cells were washed once with serum-containing
medium, once with PBS, once with annexin V-FITC buffer (10 mM
Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl
 
2
 
), and incubated for
15 min at room temperature with annexin V-FITC (Bender MedSystems)
at a final concentration of 2.5 
 
m
 
g/ml in annexin V buffer. After washing
once with annexin V buffer, the samples were resuspended in the same
buffer and analyzed by flow cytometry. Immediately before analysis, pro-
pidium iodide was added to a final concentration of 5 
 
m
 
g/ml to distinguish
apoptotic from necrotic cells, and 5,000 cells were analyzed for each
sample.
For ApopTag reactions, cells were harvested as described above, fixed
in 1% paraformaldehyde for 15 min on ice, and washed twice with PBS.
The samples were resuspended in 1 ml ice-cold 70% ethanol and stored at
 
2
 
20
 
8
 
C overnight. After centrifugation at 2,500 rpm for 15 min, cells were
washed two times in PBS before performing ApopTag reactions (Oncor)
according to the manufacturer’s recommendations. These samples were
analyzed by flow cytometry.
For in situ analysis of apoptosis in cells transfected transiently with the
green fluorescent protein (GFP)–expressing vector pEGFP-1 (CLON-
TECH Laboratories) and dnAKT/PKB, the transfected cells were stained
with annexin V-PE (PharMingen) according to the manufacturer’s direc-
tions, and plated on coverslips. The percentage of GFP-positive cells that
was annexin V-PE–positive was determined by fluorescence microscopy.
A total of at least 80 GFP-positive cells from at least 10 microscopic fields
were analyzed for each data point.
 
Analysis of AKT/PKB Expression and Activity
 
To assess the expression of endogenous AKT/PKB protein, cells were in-
 
1. 
 
Abbreviations used in this paper: 
 
CAD, caspase-activated deoxyribonu-
clease; dnAKT, dominant negative AKT; dnp53, dominant negative p53;
GFP, green fluorescent protein; HA, hemagglutinin; tsp53, temperature-
sensitive p53. 
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cubated with either rat Ig or 439-9B as described above in the presence of
either DMSO (1:500), a caspase 3 inhibitor (Z-DEVD-FMK; Calbiochem-
Novabiochem; 4 
 
m
 
g/ml), or a caspase 8 inhibitor (Z-IETD-FMK; Calbio-
chem-Novabiochem; 4 
 
m
 
g/ml). After washing with PBS, the cells were
plated in serum-free medium containing 1% BSA in wells of a 12-well
plate that had been coated with anti–rat Ig (13.5 
 
m
 
g/ml) and blocked for
1 h at 37
 
8
 
C with 1% BSA-containing medium. After a 1-h stimulation, ad-
herent and suspension cells were harvested and extracted with AKT/PKB
lysis buffer (20 mM Tris, pH 7.4, 0.14 M NaCl, 1% NP-40, 10% glycerol, 2
mM PMSF, 5 
 
m
 
g/ml aprotinin, 5 
 
m
 
g/ml pepstatin, 50 
 
m
 
g/ml leupeptin, 1
mM sodium orthovanadate). After removing cellular debris by centrifuga-
tion at 12,000 
 
g
 
 for 10 min, equivalent amounts of total cell protein from
these extracts were resolved by SDS-PAGE (8%) and transferred to ni-
trocellulose. The blots were probed with a rabbit anti-AKT/PKB antise-
rum, followed by HRP-conjugated goat anti–rabbit Ig, and the immunore-
active bands were visualized by enhanced chemiluminescence. These blots
were also probed with a rabbit antiserum specific for actin to confirm the
loading of equivalent amounts of protein. Relative AKT/PKB and actin
expression levels were assessed by densitometry using IP Lab Spectrum
software (Scanalytics).
To determine the level of serine 473–phosphorylated AKT/PKB, cells
were transfected transiently using the Lipofectamine reagent (GIBCO
BRL) with an HA-tagged AKT/PKB cDNA (provided by A. Toker, Bos-
ton Biomedical Research Institute, Boston, MA). 20 h after transfection,
these cells were harvested by trypsinization and subjected to antibody-
mediated integrin clustering. Specifically, cells were incubated on ice for
30 min with either control rat IgG or 439-9B at a concentration of 10 
 
m
 
g/ml.
After washing with PBS, the cells were plated in serum-free medium con-
taining 1% BSA onto wells of a 60-mM tissue culture dish that had been
coated at 4
 
8
 
C with anti–rat Ig (13.5 
 
m
 
g/ml) and blocked for 1 h at 37
 
8
 
C in
1% BSA-containing medium. After 1 h, adherent and suspension cells
were harvested and washed twice with PBS. Proteins from these cells were
extracted with AKT/PKB lysis buffer (see above). After removing cellular
debris by centrifugation at 12,000 
 
g
 
 for 10 min at 4
 
8
 
C, equivalent amounts
of total cellular protein were precleared with a 1:1 mixture of protein A
and protein G–Sepharose for 1 h at 4
 
8
 
C. Immunoprecipitations were per-
formed for 1 h on these precleared lysates using an HA-specific mAb (1
 
m
 
g; Boehringer Mannheim) and protein A/protein G–Sepharose beads.
Proteins from these immunoprecipitates were subjected to reducing SDS-
PAGE (8%), transferred to nitrocellulose, and probed with an AKT/PKB
phosphoserine 473–specific rabbit antiserum (New England Biolabs) fol-
lowed by HRP-conjugated goat anti–rabbit IgG. Phospho-AKT/PKB was
detected on these blots by chemiluminescence (Pierce Chemical Co.).
These samples were also probed with rabbit anti-AKT/PKB. The relative
intensity of phosphoserine AKT/PKB and AKT/PKB bands was assessed
by densitometry, as described above.
 
Analysis of AKT/PKB Proteolysis
 
Baculovirus-expressed AKT/PKB (0.5 
 
m
 
g; provided by A. Toker) was in-
cubated with either active recombinant caspase 8 (2 mg; Calbiochem-Nova-
biochem) or active recombinant caspase 3 (2 
 
m
 
g; Calbiochem-Novabio-
chem) at 37
 
8
 
C for 1 h in a final volume of 10 
 
m
 
l. Subsequently, the reaction
mixtures were divided into two aliquots and resolved by SDS-PAGE
(8%). The gels were silver stained using the GelCode SilverSNAP Stain
Kit (Pierce Chemical Co.) or transferred to nitrocellulose and probed with
a rabbit AKT/PKB antiserum as described above.
 
Results
The a6b4 Integrin Promotes the Survival of
p53-deficient, but Not p53 Wild-type Carcinoma Cells
For our initial experiments, we used stable b4 transfec-
tants of two a6b4-deficient carcinoma cell lines that differ
in their p53 status: RKO colon carcinoma cells, which ex-
press wild-type p53 (Nagasawa et al., 1995); and MDA-
MB-435 breast carcinoma cells, which express a mutant,
inactive form of p53 (Lesoon-Wood et al., 1995). We also
used RKO and MDA-MB-435 cells that express a cyto-
plasmic domain deletion mutant of a6b4 (RKO/b4-Dcyt;
MDA/b4-Dcyt) that is signaling deficient. The character-
ization of these cells has been described previously
(Clarke et al., 1995; Shaw et al., 1997).
To explore the potential influence of a6b4 expression
on the survival of serum-starved carcinoma cells deprived
of matrix attachment, the a6b4 and a6b4-Dcyt–expressing
RKO and MDA-MB-435 subclones were plated on poly-
L-lysine in serum-free medium. The level of apoptosis in
these populations was determined either by staining with
annexin V-FITC to detect cells in the early stages of apop-
tosis or by performing terminal deoxynucleotidyl trans-
Figure 1. p53 inhibits a6b4-mediated survival. MDA-MB-435,
RKO, and RKO 1 dnp53 cells that expressed either a6b4 (b4) or
a6b4-Dcyt (b4-Dcyt) were plated on poly-L-lysine–coated tissue
culture wells and cultured in the absence of serum. After 15 h,
the cells were harvested, subjected to either ApopTag reactions
(A) or annexin V-FITC staining (B), and analyzed by flow cy-
tometry. A survival effect of a6b4 was quantified by subtracting
the percentage of a6b4-expressing cells that were positive for ei-
ther Apoptag (A) or annexin V-FITC (B) staining from the per-
centage of a6b4-Dcyt–expressing cells that were positive for
these markers. This value was plotted on the bar graphs shown in
A and B, with positive values indicating that the specified b4
clone exhibits increased survival relative to the relevant b4-Dcyt
subclone, and negative values indicating an increased apoptosis
of the indicated clone relative to the appropriate b4-Dcyt clone.
The data in A represent the means (6 SEM) from three indepen-
dent experiments. Similar results to those shown in B were ob-
served in three separate trials.The Journal of Cell Biology, Volume 147, 1999 1066
ferase end labeling reactions (Apoptag) to detect DNA
fragmentation (Fig. 1). In addition, we assessed the viabil-
ity of these serum-deprived cells by measuring the cellular
uptake of propidium iodide (Table I). The ability of a6b4
to promote the survival of these cells was determined by
subtracting the percent apoptotic a6b4-expressing cells
from the percent apoptotic a6b4-Dcyt–expressing cells.
The expression of a6b4 in MDA-MB-435 cells signifi-
cantly increased the survival of these cells relative to
MDA-MB-435 cells expressing a6b4-Dcyt, as assessed by
annexin V-FITC staining (Fig. 1), ApopTag staining (Fig.
1), and propidium iodide uptake (Table I). In contrast, the
expression of a6b4 in RKO cells did not increase the sur-
vival of these cells relative to either the mock (Table I) or
RKO/b4-Dcyt transfectants (Fig. 1). In fact, we observed a
higher level of apoptosis and cell death in serum-starved
RKO/b4 as compared with RKO/b4-Dcyt cells, in agree-
ment with our previous demonstration that a6b4 can pro-
mote apoptosis in wild-type p53 carcinoma cells (Bach-
elder et al., 1999).
Based on the fact that RKO and MDA-MB-435 cells
differ in their p53 status, we reasoned that the ability of
a6b4 to promote cell survival may be inhibited by p53.
This hypothesis was examined by investigating the effect
of a6b4 expression on the survival of RKO cells in which
p53 activity had been inhibited by the expression of a
dnp53 construct. Indeed, a6b4 expression promoted the
survival of serum-starved, dnp53-expressing RKO cells as
determined by ApopTag and annexin V-FITC staining
(Fig. 1). These results demonstrate that p53 can suppress
the survival signaling mediated by a6b4 in serum-starved
carcinoma cells.
a6b4-Mediated Survival in p53-deficient Carcinoma 
Cells Is Inhibited by Dominant Negative AKT/PKB
Given the importance of the AKT/PKB kinase in numer-
ous survival signaling pathways (Ahmed et al., 1997; Datta
et al., 1997; Dudek et al., 1997; Songyang et al., 1997;
Blume-Jensen et al., 1998; Crowder and Freeman, 1998;
Gerber et al., 1998), we investigated whether the survival
function of a6b4 in serum-starved, p53-deficient carcinoma
cells was AKT/PKB–dependent. The MDA-MB-435/b4–
transfected clones, as well as the parental cells, were
cotransfected with plasmids encoding for GFP and an HA-
tagged, kinase-deficient AKT/PKB mutant that acts as a
dominant negative construct (dnAKT/PKB) (Dudek et al.,
1997; Skorski et al., 1997; Eves et al., 1998). Expression of
this dnAKT/PKB construct was confirmed by immuno-
blotting extracts from these transfected cells with an HA-
specific mAb (data not shown). After 15 h of serum star-
vation, the level of apoptosis in GFP-positive cells was
assessed by annexin V-PE staining. As shown in Fig. 2,
MDA-MB-435/b4 clones demonstrated significantly less
apoptosis than parental MDA-MB-435 cells in agreement
with the data shown in Table I. Importantly, dnAKT/PKB
expression inhibited this a6b4 survival function in each of
the two MDA-MB-435/b4 clones examined, but it did not
alter the level of apoptosis in parental MDA-MB-435 cells.
p53 Inhibits the Activation of AKT/PKB by a6b4
To understand the mechanism by which p53 inhibits a6b4-
mediated survival, we investigated the possibility that p53
alters the ability of this integrin to activate AKT/PKB. Ini-
tially, we examined whether the antibody-mediated clus-
tering of a6b4 in MDA-MB-435 cells resulted in the phos-
phorylation of AKT/PKB on serine 473, an event that has
been shown to correlate with AKT/PKB activation (Alessi
et al., 1996). MDA-MB-435/b4 subclones were transfected
with an HA-tagged AKT/PKB construct. These cells were
incubated with either a control rat IgG or the b4-specific
antibody 439-9B and plated in the absence of serum on
secondary antibody–coated tissue culture wells for 1 h.
HA immunoprecipitations were performed on extracts
from these cells, and the levels of serine-phosphorylated
AKT/PKB were assessed by blotting these immunoprecip-
itates with an antiserum specific for AKT/PKB molecules
phosphorylated on serine residue 473. As shown in Fig. 3
A, the antibody-mediated clustering of a6b4 stimulated an
increase in the level of serine-phosphorylated AKT/PKB
in each of the two MDA-MB-435/b4 subclones relative to
control cells (2.1-fold increase, b4 clone 1; 5.5-fold in-
crease, b4 clone 2). This a6b4-induced increase in AKT/
Table I. Influence of a6b4 Integrin on the Viability of RKO and 
MDA-MB-435 Cells
Clone
Percent propidium
iodide–positive cells
MDA/Mock 21
b4 Clone 1 13
b4 Clone 2 9
RKO/Mock 32
b4 Clone 1 49
b4 Clone 2 47
Mock-transfected and b4-transfected MDA-MB-435 and RKO cells were plated on
poly-L-lysine (25 mg/mL) in the absence of serum for 15 h, harvested, and incubated
with propidium iodide (PI). The percentage of PI-positive cells was assessed by flow
cytometry. Similar results were observed in four independent experiments.
Figure 2. Expression of a dominant negative AKT/PKB inhibits
a6b4-mediated survival. Parental (neo) and a6b4-expressing
(b4) MDA-MB-435 cells were transfected with either a GFP-
expressing plasmid (mock) or both a GFP and a dnAKT/PKB–
expressing construct (dnAKT/PKB), plated on poly-L-lysine, and
cultured for 15 h in the absence of serum. Apoptosis in these cells
was assessed by annexin V-PE staining. The data are reported as
the percentage of GFP-positive cells that were stained by an-
nexin V-PE. Similar results were observed in two additional ex-
periments.Bachelder et al. p53 Inhibition of a6b4 Integrin-mediated Survival 1067
PKB serine phosphorylation was dependent on a6b4
signaling based on the inability of a6b4-Dcyt clustering
to increase the level of the serine 473–phosphorylated
AKT/PKB in MDA-MB-435/b4-Dcyt subclones (data not
shown).
To investigate the influence of p53 on the activation of
AKT/PKB by a6b4, we explored whether a6b4 clustering
induced the phosphorylation of AKT/PKB on serine resi-
due 473 in MDA-MB-435/b4 that had been reconstituted
with functional p53. Specifically, MDA-MB-435/b4 cells
were transfected with a temperature-sensitive mutant of
human p53 (tsp53) that assumes a functional conformation
at 328C but not at 378C (Zhang et al., 1994). This construct
has been used extensively to study the influence of p53 on
signaling pathways involved in cell growth and apoptosis
(Kobayashi et al., 1995; Owen-Schaub et al., 1995). Stable
transfectants of these cells were selected, and tsp53 ex-
pression was confirmed by immunoblotting (data not
shown). Tsp53 and mock-transfected cells were trans-
fected transiently with HA-AKT/PKB. After incubating
these cells with either rat IgG or 439-9B, they were plated
on secondary antibody–coated wells and subjected to a
328C incubation to stimulate p53 activity, followed by a
378C incubation to activate AKT/PKB. HA immunopre-
cipitations were performed on extracts from these cells,
and these immunoprecipitates were subjected to immuno-
blotting with phosphoserine 473 AKT/PKB–specific rabbit
antiserum. As shown in Fig. 3 B, the clustering of a6b4 sig-
nificantly increased the level of phosphoserine 473-AKT/
PKB in mock-transfected MDA/b4 cells (7.9-fold in-
crease), but not in tsp53-expressing MDA/b4 cells (1.2-
fold increase). The importance of p53 in the inhibition of
the a6b4-associated activation of AKT/PKB was indicated
by the finding that a6b4 clustering increased the level of
phosphoserine 473 AKT/PKB in MDA/b4 1 tsp53 trans-
fectants that had been incubated at 378C, the nonpermis-
sive temperature for this tsp53 construct (data not shown).
The ability of p53 to suppress the a6b4-mediated activa-
tion of AKT/PKB was explored further in RKO carci-
noma cells, which express wild-type p53. In agreement
with the results obtained in MDA/b4 cells that had been
reconstituted with functional p53, the clustering of a6b4
in two independent RKO/b4 subclones did not result in
increased amounts of serine phosphorylated AKT/PKB
(Fig. 3 C and data not shown). Importantly, the expression
of dnp53 in RKO/b4 cells restored the ability of a6b4 to
activate AKT/PKB, as evidenced by an increase in phos-
phoserine 473-AKT/PKB immunoreactivity in RKO/b4 1
dnp53 cells that had been subjected to antibody-mediated
a6b4 clustering (8.6-fold increase), as described above
(Fig. 3 C). The ability of a6b4 to stimulate AKT/PKB ac-
tivity in RKO/b4 1 dnp53 cells but not in RKO/b4 cells
was confirmed by performing in vitro kinase assays using
histone H2B as a substrate (data not shown). As a control
for specificity, we also demonstrated that the clustering of
a6b4 on dnp53-expressing RKO/b4-Dcyt cells did not
stimulate AKT/PKB activity (data not shown).
a6b4 Stimulation Induces the Caspase 3–dependent 
Cleavage of AKT/PKB in a p53-dependent Manner
To define the mechanism by which p53 inhibits the ability
of a6b4 to activate AKT/PKB, we investigated whether
p53 alters AKT/PKB expression levels in response to a6b4
clustering. RKO/b4 and RKO/b4 1 dnp53-expressing cells
were incubated with either rat Ig or 439-9B and stimulated
on secondary antibody–coated wells for 1 h. The amount
of total AKT/PKB in equivalent amounts of total protein
from these lysates was assessed by immunoblotting. Im-
portantly, the antibody-mediated clustering of the a6b4
integrin on each of two RKO/b4 subclones resulted in a
significant reduction in the total level of AKT/PKB in
these cells (Fig. 4 A). In contrast, AKT/PKB levels were
not reduced in dnp53-expressing RKO/b4 cells (Fig. 4 B)
or in MDA-MB-435/b4 subclones (data not shown) after
the antibody-mediated clustering of a6b4. We also ob-
served decreased levels of HA-AKT/PKB protein in HA-
AKT/PKB–transfected RKO/b4 cells, but not in HA-
AKT/PKB–transfected RKO/b4 1 dnp53 cells upon the
antibody-mediated clustering of a6b4 (data not shown).
Based on the reported ability of caspases to cleave sig-
naling molecules that promote cell survival (Cheng et al.,
Figure 3. p53 inhibits the ability of a6b4 to induce AKT/PKB
phosphorylation in carcinoma cells. MDA/b4, MDA/b4 1 tsp53,
RKO/b4, and RKO/b4 1 dnp53 cells were transfected transiently
with an HA-tagged AKT/PKB. These transfectants were incu-
bated with the indicated primary antibodies, washed, and plated
in the absence of serum on secondary antibody–coated tissue cul-
ture wells. HA-AKT/PKB–transfected MDA/b4 (A), RKO/b4
(C), and RKO/b4 1 dnp53 (C) cells were stimulated for 1 h at
378C. Alternatively, mock- and tsp53-transfected MDA/b4 cells
(B) were stimulated for 1 h at 328C to activate tsp53, followed by
an additional hour at 378C to activate AKT/PKB. Immunoprecip-
itations were performed with an HA-specific mAb on equal
amounts of total extracted protein. The immunoprecipitates were
resolved by SDS-PAGE (8%), transferred to nitrocellulose, and
probed with a phosphoserine 473 AKT/PKB–specific rabbit anti-
serum (New England Biolabs), followed by HRP-conjugated
goat anti–rabbit IgG. Phosphoserine-specific AKT/PKB bands
were detected by chemiluminescence, and are noted by arrows.The Journal of Cell Biology, Volume 147, 1999 1068
1997; Enari et al., 1998; Sakahira et al., 1998), we hypoth-
esized that a6b4 may promote the caspase-dependent
cleavage of AKT/PKB in wild-type p53-expressing car-
cinoma cells. Initially, we explored the importance of
caspase 3 activity, which has been shown to play a crucial
role in p53-dependent apoptotic pathways (Fuchs et al.,
1997), in the a6b4-associated reduction of AKT/PKB ex-
pression levels. In agreement with the data shown in Fig. 4,
the clustering of a6b4 in control RKO/b4 cells signifi-
cantly reduced the level of AKT/PKB in these carcinoma
cells (Fig. 5). However, RKO/b4 cells that had been pre-
treated with Z-DEVD-FMK, a cell permeable caspase 3
inhibitor, did not exhibit decreased levels of AKT/PKB in
response to a6b4 clustering (Fig. 5). In contrast, we de-
tected a decreased amount of AKT/PKB after the cluster-
ing of a6b4 in RKO/b4 cells that had been pretreated with
Z-IETD-FMK, a cell permeable caspase 8 inhibitor (Fig.
5). Importantly, no effect of these inhibitors on AKT/PKB
levels was observed upon the clustering of a6b4 on RKO/
a6b4-Dcyt cells (data not shown).
The ability of the caspase 3 inhibitor to restore normal
AKT/PKB levels suggested that AKT/PKB is cleaved by
caspase 3 upon the clustering of a6b4 in carcinoma cells
expressing wild-type p53. To establish the caspase 3–medi-
ated cleavage of AKT/PKB more rigorously, we investi-
gated whether a recombinant form of this cysteine pro-
tease could cleave baculovirus-expressed AKT/PKB in
vitro. Proteins in these reactions were resolved by SDS-
PAGE and detected by silver staining. The results obtained
revealed that the incubation of baculovirus-expressed
AKT/PKB (Mr, 60 kD) with recombinant caspase 3 re-
sulted in the formation of an AKT/PKB cleavage product
(Mr, 49 kD) (Fig. 6). In contrast, we did not detect an
AKT/PKB cleavage product after the incubation of bacu-
lovirus AKT/PKB with recombinant caspase 8 (Fig. 6).
The caspase 3–generated AKT/PKB cleavage product was
also detected by immunoblotting with an antiserum spe-
cific for the carboxy terminus of AKT/PKB, suggesting
that caspase 3 cleaves AKT/PKB at its amino terminus
(data not shown).
Finally, to demonstrate that the caspase 3–dependent
cleavage of AKT/PKB was responsible for the p53 inhibi-
tion of AKT/PKB activity in RKO/b4 cells, we explored
the effects of a caspase 3 inhibitor on the ability of a6b4 to
activate AKT/PKB. HA-AKT/PKB–transfected RKO/b4
cells were subjected to antibody-mediated a6b4 clustering
in the presence of either DMSO or the caspase 3 inhibitor
Z-DEVD-FMK. HA immunoprecipitates from extracts
from these cells were subjected to immunoblotting with
the phosphoserine 473 AKT/PKB–specific rabbit antise-
rum. As shown in Fig. 7, the pretreatment of RKO/b4 cells
with Z-DEVD-FMK restored the ability of a6b4 to stimu-
late the phosphorylation of AKT/PKB in these cells.
These results demonstrate that a6b4 stimulates the cas-
pase 3–dependent cleavage and inactivation of AKT/PKB
in p53 wild-type, but not in p53-deficient carcinoma cells.
Discussion
The binding of extracellular matrix proteins to integrins
initiates survival signals that inhibit anoikis, a form of apop-
tosis induced upon the detachment of cells from extracel-
lular matrix (Meredith et al., 1993; Frisch and Francis,
Figure 4. Clustering of the a6b4
integrin reduces AKT/PKB pro-
tein levels in p53-wild type but
not in p53-deficient carcinoma
cells. RKO/b4 (A and B) and
RKO/b4  1 dnp53 (B)–express-
ing cells were incubated with ei-
ther rat Ig or 439-9B and plated
on secondary antibody–coated
wells for 1 h in the absence of se-
rum. Equivalent amounts of to-
tal protein from lysates from
these cells were resolved by
SDS-PAGE (8%), transferred to
nitrocellulose, and probed with
an AKT/PKB–specific rabbit an-
tiserum (New England Biolabs)
followed by HRP-conjugated
goat anti–rabbit IgG. These
blots were also probed with an
actin-specific rabbit antiserum
(Sigma Chemical Co.) to con-
firm the loading of equivalent amounts of protein. The AKT/
PKB and actin bands were detected by enhanced chemilumines-
cence, and are indicated by arrows. These bands were quantified
by densitometry. a6b4 clustering decreased AKT/PKB levels in
RKO/b4 subclones (1.7-fold decrease, b4 clone 1; 1.9-fold de-
crease, b4 clone 2), but not in RKO/b4 1 dnp53 cells. Similar re-
sults were observed in four additional trials.
Figure 5. A caspase 3 inhibitor blocks a6b4-associated reduc-
tions in AKT/PKB protein levels. RKO/b4 cells were incubated
with either rat Ig or 439-9B in the presence of DMSO (1:500), a
caspase 3 inhibitor (Z-DEVD-FMK; 4 mg/ml), or a caspase 8 in-
hibitor (Z-IETD-FMK; 4 mg/ml). These cells were washed with
PBS and plated onto secondary antibody–coated wells in the
presence of the same drugs for 1 h in serum-free medium. Equiv-
alent amounts of total protein were resolved by SDS-PAGE
(8%), transferred to nitrocellulose, and probed with an AKT/
PKB–specific rabbit antiserum (New England Biolabs) followed
by HRP-conjugated goat anti–rabbit IgG. AKT/PKB was de-
tected by enhanced chemiluminescence and quantified by densi-
tometry. The antibody-mediated clustering of a6b4 decreased
the level of AKT/PKB in DMSO-treated cells (2.0-fold decrease,
b4 clone 1; 1.9-fold decrease, b4 clone 2), as well as in cells pre-
treated with a caspase 8 inhibitor (1.9-fold decrease). In contrast,
the pretreatment of these cells with a caspase 3 inhibitor partially
restored AKT/PKB levels in RKO/b4 cells subjected to a6b4
clustering (1.1-fold decrease, b4 clone 1; 1.1-fold decrease, b4
clone 2). By probing these blots with an actin-specific rabbit anti-
serum (Sigma Chemical Co.), we confirmed that equivalent
amounts of actin were present in each lane (data not shown).
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1994). In the current studies, we show that the a6b4 inte-
grin suppresses anoikis exclusively in carcinoma cells that
lack functional p53. Furthermore, we demonstrate that
this  a6b4-associated survival function depends on the abil-
ity of this integrin to activate the serine/threonine kinase
AKT/PKB in p53-deficient cells. Finally, we provide evi-
dence that p53 inhibits the a6b4-mediated activation of
AKT/PKB by promoting the caspase 3–dependent cleav-
age of this kinase. Collectively, our findings establish that
p53 can inhibit an integrin-associated survival function, a
phenomenon that has important implications for tumor
cell growth.
Our results suggest that the a6b4 integrin can enhance
the survival of carcinoma cells in an AKT/PKB–depen-
dent manner. Although previous studies have shown that
cell attachment to matrix proteins promotes the survival of
primary epithelial cells (Khwaja et al., 1997; Farrelly et al.,
1999), a6b4 is the first specific integrin to be implicated in
the delivery of AKT/PKB–dependent survival signals to
carcinoma cells. The importance of AKT/PKB in a6b4
survival signaling was indicated in our studies by the abil-
ity of a dnAKT/PKB construct containing inactivating mu-
tations in the catalytic domain to inhibit the survival effect
of a6b4 in serum-starved MDA-MB-435 cells. Although
this dnAKT/PKB has been used extensively to implicate
AKT/PKB in survival pathways, it is possible that it associ-
ates with phosphoinositide-dependent kinases and inhibits
their activity. However, our observation that the expres-
sion of a constitutively active AKT/PKB in MDA-MBA-
435 enhances their survival (data not shown) strongly sug-
gests that a6b4 expression promotes the survival of these
cells by activating AKT/PKB.
Our demonstration that p53 can inhibit AKT/PKB ki-
nase activity is of interest in light of the recent finding that
the PTEN tumor suppressor can also inhibit cell growth by
inhibiting AKT/PKB in a manner that is dependent on its
lipid phosphatase activity (Myers et al., 1998; Stambolic et
al., 1998; Davies et al., 1999; Ramaswamy et al., 1999; Sun
et al., 1999). Together, our current findings on p53 and the
previously described activities of PTEN highlight the im-
pact of tumor suppressors on integrin-mediated functions.
Moreover, our demonstration that p53 inhibits a6b4 sur-
vival signaling by promoting the caspase-dependent cleav-
age of AKT/PKB provides a mechanistic link between tu-
mor suppressor function and the regulation of integrin
signaling, similar to the phosphatase activities of PTEN.
Although previous studies have demonstrated that cas-
pases can be activated by p53 in both cell-free systems
(Ding et al., 1998) as well as in response to DNA damage
(Fuchs et al., 1997; Yu and Little, 1998), our findings sug-
gest that caspases can also be activated by an integrin in a
p53-dependent manner. Indeed, it will be informative to
determine if other activators of p53 such as DNA damage
(Siegel et al., 1995; Komarova et al., 1997) can promote
the caspase-dependent cleavage of AKT/PKB.
The finding that AKT/PKB activity can be regulated by
caspase 3 substantiates the hypothesis that caspases play
an important role in many forms of apoptosis based on
their ability to cleave signaling molecules that influence
cell survival. For example, caspases have been shown to
cleave and inactivate an inhibitor of caspase-activated
deoxyribonuclease (CAD). Importantly, the cleavage of
this inhibitor results in the activation of CAD, which is the
enzyme responsible for the DNA fragmentation that is
characteristic of apoptosis (Enari et al., 1998; Sakahira et
al., 1998). Caspase 3 has also been shown to cleave bcl-2,
resulting in an inhibition of its anti-apoptotic function
(Cheng et al., 1997). While AKT/PKB has been suggested
to be a target of caspase activity based on the reduced lev-
els of this kinase observed in T cells in response to fas
stimulation (Widmann et al., 1998), our results extend this
finding by establishing definitively that AKT/PKB is
cleaved by caspase 3. More importantly, we provide evi-
dence that this cleavage event results in the inhibition of
AKT/PKB kinase activity, and implicate this event in the
inhibition of a6b4 integrin survival function.
It is important to consider the mechanism by which the
a6b4-induced, caspase-dependent cleavage of AKT/PKB
inhibits its kinase activity. We detected an AKT/PKB frag-
ment (Mr, 49 kD) after the in vitro incubation of AKT/
Figure 6. AKT/PKB is cleaved by recombinant caspase 3 in vitro.
Baculovirus-expressed AKT/PKB (0.5 mg) was incubated either
alone, with recombinant caspase 3 (2 mg) or with recombinant
caspase 8 (2 mg) for 1 h at 378C. Proteins in these reactions were
resolved by SDS-PAGE (8%) and subjected to silver staining.
AKT/PKB and its cleavage product are indicated by arrows. Sim-
ilar results were observed in three trials.
Figure 7. A caspase 3 inhibitor restores the ability of a6b4 to in-
duce AKT/PKB phosphorylation. HA-AKT/PKB–transfected
RKO/b4 cells were incubated with either rat Ig or 439-9B in the
presence of DMSO (1:500) or a caspase 3 inhibitor (Z-DEVD-
FMK; 4 mg/ml). After washing with PBS, these cells were plated
on secondary antibody–coated wells in serum-free medium con-
taining the indicated drugs for 1 h. HA immunoprecipitations
were performed on equivalent amounts of total extracted protein
from these samples. These immunoprecipitates were resolved by
SDS-PAGE (8%), transferred to nitrocellulose, and probed with
rabbit antiserum specific for phosphoserine 473-AKT/PKB, fol-
lowed by HRP-conjugated goat anti–rabbit Ig. Phosphoserine
473-AKT/PKB was detected by enhanced chemiluminescence,
and is indicated by an arrow. Total AKT/PKB levels were also as-
sessed by stripping these membranes and probing with an AKT/
PKB–specific rabbit antiserum (data not shown). Relative activ-
ity was assessed by determining the ratio of serine phosphory-
lated AKT/PKB to that of total AKT/PKB for each sample (rela-
tive AKT activity: lane 1 5 1.0; lane 2 5 1.3; lane 3 5 1.1; and
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PKB with recombinant caspase 3. This fragment was rec-
ognized by a rabbit antiserum raised against a peptide cor-
responding to the extreme carboxy-terminal amino acids
of the molecule, suggesting that caspase 3 cleaves AKT/
PKB at its amino terminus. Interestingly, the pleckstrin
homology domain, which resides in the amino terminus of
AKT/PKB, is important in both the translocation of this
kinase to the membrane and its subsequent activation
(Franke et al., 1995; Andjelkovic et al., 1997). It is possible
that the caspase 3–dependent cleavage of AKT/PKB pre-
vents the membrane translocation of this kinase, thus, pre-
venting its activation. However, we were unable to iden-
tify an AKT/PKB fragment in vivo after the clustering of
a6b4, despite our detection of reduced AKT/PKB levels
under these conditions. This result suggests that after the
initial cleavage of AKT/PKB by caspase 3, this kinase is
subjected to further cleavage by other caspases, as has
been shown for ICAD (Tang and Kidd, 1998). Moreover,
our inability to detect AKT/PKB fragments in vivo after
the clustering of a6b4 suggests that AKT/PKB cannot be
detected by immunoblotting after its cleavage by multiple
caspases. The ability of a caspase 3 inhibitor to restore
both normal AKT/PKB levels as well as the a6b4-medi-
ated activation of AKT/PKB suggests that the degradation
of AKT/PKB observed in vivo is dependent on the initial
cleavage of this kinase by caspase 3.
In contrast to our finding that p53-dependent, caspase 3
activity inhibits AKT/PKB, other studies have concluded
that constitutively active AKT/PKB can delay p53-depen-
dent apoptosis (Sabbatini and McCormick, 1999), inhibit
caspases (Cardone et al., 1998), and block caspase-depen-
dent forms of apoptosis (Berra et al., 1998; Gibson et al.,
1999). The demonstrated ability of AKT/PKB to inhibit
p53 and caspase activity in these studies may relate to the
kinetics of AKT/PKB activation. Specifically, the rapid
stimulation of AKT/PKB may impede p53 or caspase acti-
vation. In contrast, the ability of a6b4 clustering to pro-
mote the caspase 3–dependent inactivation of AKT/PKB
in p53 wild-type carcinoma cells may relate to the fact that
a6b4 signaling stimulates caspase activity before AKT/
PKB activity in these cells. Alternatively, it is possible that
the ability of caspase 3 to cleave AKT/PKB was not ob-
served in previous studies because insufficient amounts of
endogenous caspase activity were present to inhibit the ac-
tivity of exogenously introduced, active AKT/PKB. None-
theless, these results suggest that an intimate crosstalk ex-
ists between AKT/PKB and caspases that contributes to
the regulation of cell survival.
We have previously demonstrated that the a6b4 inte-
grin activates p53 function (Bachelder et al., 1999). The
current studies describe an important consequence of this
a6b4 activity, namely the inhibition of AKT/PKB activity
and its associated cell survival function. Similar to previ-
ous results from our laboratory (Clarke et al., 1995; Shaw
et al., 1997; O’Connor et al., 1998) and others (Kim et al.,
1997; Sun et al., 1998), the current studies demonstrate
that the survival function of a6b4 is ligand-independent in
b4-transfected, p53-deficient carcinoma cells. This ligand-
independent survival function may be attributable to the
ability of the b4 cytoplasmic domain to self-associate
(Rezniczek et al., 1998).
In addition to demonstrating that p53 inhibits a6b4-
mediated survival, we observed that a6b4 increases the
level of apoptosis observed in serum-starved p53 wild-type
carcinoma cells. This result suggests that the apoptotic sig-
naling pathway activated by a6b4 can augment the apop-
totic signaling initiated by serum deprivation. Although
p53 has been implicated in the apoptosis induced in endo-
thelial cells upon their detachment from matrix (Ilic et al.,
1998), others have reported that epithelial cell anoikis is
p53-independent (Boudreau et al., 1995). In agreement
with the results of the latter study, we observed apoptosis
in p53-deficient cells, including MDA-MB-435 cells and
dnp53-expressing RKO cells, upon their detachment from
matrix. These results indicate that carcinoma cells are sub-
ject to a p53-independent form of anoikis. In combination
with our previous observation that a6b4 apoptotic signaling
requires p53 activity (Bachelder et al., 1999), our findings
suggest that the p53-independent apoptosis of carcinoma
cells that occurs in response to matrix detachment can be
enhanced by p53-dependent, a6b4 apoptotic signaling.
The current studies may explain why the a6b4 integrin
has been implicated in the apoptosis of some cells and the
survival of others. Specifically, a6b4 has been shown to in-
duce growth arrest and apoptosis in several carcinoma cell
lines (Clarke et al., 1995; Kim et al., 1997, Sun et al., 1998)
as well as in endothelial cells (Miao et al., 1997). However,
this integrin has also been shown to promote the prolifera-
tion (Mainiero et al., 1997; Murgia et al., 1998) and sur-
vival (Dowling et al., 1996) of keratinocytes. These appar-
ently contradictory functions of a6b4 may relate to the
fact that the functions of a6b4 are cell type–specific. The
current studies establish that the p53 tumor suppressor is
one critical signaling molecule that may influence a6b4
function in different cell types because this integrin pro-
motes apoptosis only in wild-type p53-expressing cells and
survival only in p53-deficient cells. Interestingly, the re-
ported ability of a6b4 to promote keratinocyte survival
(Dowling et al., 1996) may relate to the reported defi-
ciency of p53 activity in these cells (Nigro et al., 1997).
One implication of our findings is that the a6b4 integrin
is similar to a number of oncogenes that promote cell pro-
liferation in some settings and cell death in others. The re-
cent observation that oncogenes can deliver such death
signals has led to their seemingly contradictory categoriza-
tion as tumor suppressors in select environments. For ex-
ample, although the stimulation of c-myc and E2F nor-
mally promotes cell proliferation, the activation of these
oncogenes induces apoptosis in the presence of secondary
stress signals such as p53 expression, serum starvation or
hypoxia (Evan et al., 1992; Shi et al., 1992, Hermeking and
Eick, 1994; Qin et al., 1994; Wu and Levine, 1994). The
ability of these stress signals to stimulate oncogene-depen-
dent apoptosis is thought to be important in eliminating
tumor cells that escape normal proliferation checkpoints
as a result of oncogene expression. Similarly, the a6b4 in-
tegrin, which promotes the survival of p53-deficient cells,
could also be classified loosely as a tumor suppressor
based on its apoptotic function in carcinoma cells that ex-
press wild-type p53. The current studies demonstrate that,
similar to the activity of oncogenes, integrin function and
signaling can be profoundly influenced by physiological
stimuli that activate other signaling pathways in a cell.
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integrin to promote the survival of the p53 mutant, but not
p53 wild-type carcinoma cells. This ability of p53 to in-
fluence integrin-mediated functions so markedly derives
from its ability to activate the caspase 3–dependent cleav-
age of AKT/PKB. The fact that AKT/PKB overexpression
has been suggested to contribute to the transformed phe-
notype of tumor cells (Bellacosa et al., 1995) suggests that
the introduction of the a6b4 integrin into p53 wild-type tu-
mors may inhibit their growth by inducing the cleavage of
this transforming protein. The ability of a6b4 to induce
the p53-dependent cleavage of AKT/PKB also suggests
that the acquisition of inactivating mutations in either p53
or caspase 3 will provide a selective growth advantage for
carcinoma cells by stimulating a6b4-mediated AKT/PKB–
dependent survival signaling. Moreover, given our previ-
ous demonstration that a6b4 promotes carcinoma cell mi-
gration and invasion (Chao et al., 1996, Shaw et al., 1997;
O’Connor et al., 1998), we suggest that carcinoma cells
that express a6b4 and mutant forms of p53 or caspase 3
will have a distinct advantage in their ability to dissemi-
nate and survive as metastatic lesions.
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